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ARTICLE
Assessing Potential Drug–Drug Interactions Between 
Dabigatran Etexilate and a P- Glycoprotein Inhibitor in 
Renal Impairment Populations Using Physiologically 
Based Pharmacokinetic Modeling
Kosuke Doki1,*, Sibylle Neuhoff2, Amin Rostami-Hodjegan2,3 and Masato Homma1
Plasma concentrations of dabigatran, an active principle of prodrug dabigatran etexilate (DABE), are increased by renal im-
pairment (RI) or coadministration of a P- glycoprotein inhibitor. Because the combined effects of drug–drug interactions and 
RI have not been evaluated by means of clinical studies, the decision of DABE dosing for RI patients receiving P- glycoprotein 
inhibitors is empirical at its best. We conducted virtual drug–drug interactions studies between DABE and the P- glycoprotein 
inhibitor verapamil in RI populations using physiologically based pharmacokinetic modeling. The developed physiologically 
based pharmacokinetic model for DABE and dabigatran was used to predict trough dabigatran concentrations in the pres-
ence and absence of verapamil in virtual RI populations. The population- based physiologically based pharmacokinetic model 
provided the most appropriate dosing regimen of DABE for likely clinical scenarios, such as drug–drug interactions in this RI 
population based on available knowledge of the systems changes and in the absence of actual clinical studies.
Dabigatran etexilate (DABE), a prodrug of dabigatran (DAB), 
is an oral anticoagulant used for the prevention of stroke 
and systemic embolism in patients with nonvalvular atrial 
fibrillation.1 The prodrug is rapidly converted to the active 
moiety DAB via two primary intermediated metabolites by 
carboxylesterase (CES)- 2 in the intestine and CES- 1/CES- 2 
in the liver.2,3 Cytochrome P450 metabolic enzymes play 
no relevant role in DABE and DAB.2 Because DAB is ex-
tensively excreted in urine,2 renal impairment prolongs DAB 
elimination, thereby increasing its plasma concentrations.4 
DABE, but not DAB, is a substrate of the efflux transporter 
P- glycoprotein (P- gp),5 which results in poor oral bioavail-
ability (7.2%) because of P- gp–mediated efflux in the in-
testine.2 Therefore, concomitant use of DABE with P- gp 
inhibitors (e.g., amiodarone, quinidine, and verapamil) en-
hances the exposure to DAB.5,6 The daily DABE dose should 
be adjusted in patients with renal impairment or during the 
coadministration of a P- gp inhibitor. DABE dosing recom-
mendations for such patients vary among the European 
Union, Japan, and the United States.7–9 DABE dosing reg-
imens can be considered appropriate when the predicted 
trough concentrations are within the reported therapeutic 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
✔  The dosing regimen of dabigatran etexilate for pa-
tients with renal impairment receiving concomitant P- 
glycoprotein inhibitors has yet to be optimized through 
clinical drug–drug interaction (DDI) studies, which are 
generally conducted in healthy volunteers.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  This study explored an appropriate dosing regimen 
of dabigatran etexilate for renal impairment popula-
tions in the presence of the P- glycoprotein inhibitor ve-
rapamil using population- based physiologically based 
pharmacokinetic modeling.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  Virtual DDI studies using physiologically based 
pharmacokinetic modeling revealed that when coad-
ministered with multiple verapamil doses, the optimal 
dabigatran etexilate dosing varied among populations 
with healthy renal function and mild and moderate renal 
impairment.
HOW MIGHT THIS CHANGE DRUG DISCOVERY, 
DEVELOPMENT, AND/OR THERAPEUTICS?
✔  Virtual DDI studies through physiologically based phar-
macokinetic modeling can help simplify the optimization 
of dosing regimen for likely clinical scenarios, including 
DDIs in various renal impairment populations.
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range (28–210 ng/mL) based on the risk of major bleeding 
and ischemic stroke/systemic embolism.10 However, the 
DABE dosing regimen for patients with renal impairment 
receiving concomitant P- gp inhibitors has yet to be opti-
mized through clinical drug–drug interaction (DDI) stud-
ies, which are generally conducted in healthy volunteers. 
Although DDI liability may be different among patients with 
varying degrees of renal impairment,11 such clinical DDI 
studies in various renal impairment populations are rarely 
conducted because of obvious practical and ethical rea-
sons. Therefore, clinicians empirically decide on the dos-
ing regimens for complex DDIs in various renal impairment 
populations. The lack of specific dosing recommendations 
for more complex scenarios necessitates clinicians using 
their previous experience to personalize dosing before or 
after the start of treatment based on the patient response.12 
It has been argued that the integration of prior knowledge 
of the system (e.g., attributes associated with renal impair-
ment) together with the knowledge of its pharmacokinetic 
characteristics through physiologically based pharmaco-
kinetic (PBPK) modeling can help overcome the paucity 
of clinical data under these circumstances and avoid the 
undocumented and inconsistent guesswork while treating 
these vulnerable patients.13,14
Virtual DDI studies through PBPK modeling are alterna-
tive ways to provide appropriate dosing regimens for likely 
clinical scenarios, including DDIs in various renal impairment 
populations.12,15 PBPK models map complex drug move-
ments in the body to a physiologically realistic compartmen-
tal structure using sets of differential equations, including 
the intercorrelation between physiological parameters (e.g., 
body weight/liver volume and liver volume/hepatic blood 
flow).15 The PBPK model allows for a more accurate predic-
tion of drug disposition, including absorption, distribution, 
metabolism, and excretion, and enables the quantitative 
prediction of DDI magnitude. Upon verification, the PBPK 
model can be applied to various virtual target populations, 
including patients with renal or hepatic impairments and 
Table 1 Summary of input parameters used in the PBPK model for dabigatran etexilate 
Input parameter Initial Refined Reference/comments
Molecular weight (g/mol) 627.7 — 5
log P 3.80 — 5
Compound type Diprotic base — 5
pKa 4.0 (base), 6.7 (base) — 5
Blood/plasma ratio 1.26 — Estimated
Fraction unbound in plasma 0.063 — Estimated
Absorption
Model ADAM — —
Fraction of drug unbound in enterocyte 1 — Simcyp default
Peff,man duodenum (×10
−4 cm/s) 2.49 0.113 Estimated using Mech Peff model and scaled down (see 
Methods for details)
Peff,man jejunum I (×10
−4 cm/s) 6.27 0.206
Peff,man jejunum II (×10
−4 cm/s) 4.39 0.144
Peff,man ileum I (×10
−4 cm/s) 1.11 0.058
Peff,man ileum II (×10
−4 cm/s) 1.11 0.058
Peff,man ileum III (×10
−4 cm/s) 1.09 0.057
Peff,man ileum IV (×10
−4 cm/s) 1.05 0.055
Peff,man colon (×10
−4 cm/s) 0.58 0.0001
Distribution
Model Full PBPK — —
Vss (L/kg) 15.16 — 21
Elimination
HLS9, fu inc 0.69 — Estimated
HLS9, CES1 Km (μM) 33.5 — 3
HLS9, CES1 Vmax (pmol/min/mg) 1,174 19,462 Parameter estimation (see Methods for details)
HLS9, CES1 tissue scalar (liver/intestine) 1.0/0 — 22
HLS9, CES2 Km (μM) 15.4 — 3
HLS9, CES2 Vmax (pmol/min/mg) 30.8 9,050 Parameter estimation (see Methods for details)
HLS9, CES2 tissue scalar (liver/intestine) 0.1/0 — 22
Intestinal efflux
P- gp Km (μM) — 38.9 24
P- gp Jmax (pmol/min/cm
2) — 146 Optimized using observed data (see Methods for details)
ADAM, advanced dissolution, absorption and metabolism model; CES, carboxylesterase; fu inc, fraction of drug unbound in the incubation; HLS9, human 
liver S9 fractions; Jmax, maximum flux; Ka, absorption rate constant; Km, Michaelis–Menten constant; Mech Peff, mechanistic permeability; PBPK, physiologi-
cally based pharmacokinetic model; P- gp, P- glycoprotein; Peff,man, the effective permeability in humans; pKa, negative logarithm of the dissociation constant; 
Vmax, maximum rate of metabolism; Vss, volume of distribution at steady state.
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pediatric patients. The primary aim of this study was to ex-
plore an appropriate dosing regimen of DABE for renal im-
pairment populations in the presence of the P- gp inhibitor 
verapamil and its metabolite norverapamil using population- 
based PBPK modeling. We developed a PBPK model for 
DABE and DAB by incorporating P- gp–mediated intestinal 
efflux and applied the model to virtual DDI studies between 
DABE and verapamil in renal impairment populations.
METHODS
Model development
PBPK modeling and simulation were performed using the 
Simcyp Simulator (version 17.1; Certara, Sheffield, United 
Kingdom). Virtual populations, assuming varying levels 
of creatinine clearance (CrCl), were generated by altering 
physiological parameters, serum creatinine, and glomerular 
filtration rate range in the preverified population templates 
within the Simcyp Simulator population library (Table S1 
and Figure S1). The DABE/DAB PBPK model was devel-
oped using a middle- out approach, which uses an in vitro 
understanding of pharmacokinetic mechanisms (i.e., bot-
tom- up approach) and observed clinical data (i.e., top- down 
approach; Tables 1 and 2).16 The observed plasma con-
centration profiles of DABE and DAB were obtained from 
the literature and digitized using a GetData Graph Digitizer 
(version 2.26; http://getdata-graph-digitizer.com/).4–6,17,18
The DABE compound file was developed using the ad-
vanced dissolution, absorption, and metabolism model 
(i.e., ADAM model) that accounts for regional differences 
in permeability and P- gp–mediated efflux in the intestine 
(Table 1).19 Data on physicochemical parameters (molec-
ular weight, the logarithm of the n-octanol:buffer partition 
coefficient acid/base status, and the negative logarithm 
of the dissociation constant) were obtained from the lit-
erature.5   The fraction unbound in plasma and the blood/
plasma ratio were predicted using physicochemical pa-
rameters. In the initial model without P- gp–mediated ef-
flux in the intestine, the effective permeability in humans 
(Peff,man) for DABE was estimated using the mechanistic 
permeability model, which was developed for predicting 
the regional passive intestinal permeability of drugs in 
humans based on the knowledge of regional gut physi-
ology and drug- specific physicochemical parameters.20 
Regional Peff,man values were optimized by the scale- down 
of values estimated from the mechanistic permeability 
model when assuming that bioavailability was equiva-
lent to the observed value (7.2%).2 Drug distribution was 
modeled using a full- PBPK distribution model that uses 
a number of time- based differential equations to simu-
late concentrations in various organ compartments.21 The 
CES- 1 and CES- 2 in the liver were considered as the final 
steps of the conversion of DABE to DAB, with tissue sca-
lars of 1.0 and 0.1, respectively.3,22 The Michaelis–Menten 
kinetic parameters for the conversion of DABE to DAB by 
CES- 1 and CES- 2 were obtained from the literature.3 The 
maximum rates of metabolism for CES- 1 and CES- 2 were 
simultaneously optimized using a parameter estimation 
module from fitting with observed plasma concentration 
profiles of DABE and DAB after a single 150-mg oral dose 
of DABE.17
The DAB compound file was developed using the phys-
icochemical parameters, fraction unbound in plasma, and 
blood/plasma ratio obtained from data in the literature 
(Table 2).23 The drug distribution model was developed 
using the full- PBPK distribution model, and the predicted 
volume of distribution at steady state was matched to the 
observed value (0.96 L/kg) using a tissue-to-plasma partition 
coefficient scalar of 3.12.  Renal clearance and additional 
systemic clearance were calculated from the intravenous 
clearance (8.94 L/hour) and urinary excretion ratio (0.892) 
after a single 5-mg intravenous dose of DAB.2
The initial DABE/DAB model was refined using observed 
clinical data (“Training Sets”; Table S2)2,6 while considering 
P- gp–mediated efflux in the intestine (Tables 1 and 2). The 
P- gp–mediated efflux was described using the Michaelis–
Menten type equation (Jmax, maximum flux; Km, Michaelis–
Menten constant).  The P- gp Km value for DABE was 
obtained from the literature.24 The P- gp Jmax and regional 
Peff values were simultaneously optimized by assuming that 
bioavailability without a P- gp inhibitor and exposure ratio 
with verapamil were equivalent to observed values (7.2% 
and 1.54- fold, respectively).2,6 The Peff,man value in the colon 
was assumed to be negligibly small because the predomi-
nant compound in feces after oral DABE administration was 
DAB, which exhibited poor intestinal absorption owing to 
highly polar zwitterionic and hydrophilic natures, and DABE 
was not found in feces.2
Compound files for digoxin, verapamil (and its metabolite 
norverapamil), and quinidine in the Simcyp compound library 
were used for PBPK modeling and simulation with minor 
modifications as described in previous reports (Table S3). A 
digoxin compound file was developed using the mechanistic 
kidney model module, which accounts for glomerular filtra-
tion, passive permeability within all of the tubular segments, 
and active transport processes within the proximal tubule 
Table 2 Summary of input parameters used in the PBPK model for 
active metabolite dabigatran
Input parameter Value
Reference/
comments
Molecular weight (g/mol) 471.5 23
log P −2.21 23
Compound type Ampholyte 23
pKa 4.4 (acid),
12.4 (base)
23
Blood/plasma ratio 0.69 2
Fraction unbound in 
plasma
0.65 2
Distribution
Model Full PBPK —
Vss (L/kg) 0.96 2 (see Methods for 
details)
Elimination
Renal clearance (L/hour) 7.97 2 (see Methods for 
details)
Additional systemic 
clearance (L/hour)
0.97 2 (see Methods for 
details)
PBPK, physiologically based pharmacokinetic model; pKa, negative loga-
rithm of the dissociation constant; Vss, volume of distribution at steady state.
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segments.25 The P- gp Ki values (concentration of inhibitor 
that supports half maximal inhibition) used for norverapamil 
and quinidine were 0.3 and 0.43 μM, respectively.26,27 
Model verification
The DABE/DAB PBPK model was verified using the ob-
served DAB concentration data (“Verification Sets”; Table 
S2).4,6,8,17,18 The characteristics (age, sex distribution, and 
population/ethnicity) of virtual subjects were matched to 
those in the clinical trial. Virtual studies were simulated 
using 10 trials of 10 virtual individuals. The predicted geo-
metric mean values of the exposure parameters and DDI 
effects were compared with the corresponding observed 
values except for the use of arithmetic mean values when 
the observed geometric mean values were not available. 
The DDI simulations for digoxin were performed in a popu-
lation representative of healthy volunteers (average values 
were considered for many parameters).
Virtual DDI studies between DABE and verapamil in 
renal impairment populations
Virtual DDI studies were simulated using 20 trials of 10 
virtual individuals in a population with healthy renal func-
tion (CrCl > 80 mL/min) and in populations with mild (CrCl 
50–80 mL/min), moderate (CrCl 30–50 mL/min), and se-
vere (CrCl 15–30 mL/min) renal impairment (“Simulation 
Sets”; Table S2).  The trial design (age and proportion of fe-
males) was replicated as closely as possible to ensure that 
the characteristics of the virtual subjects were matched 
to those in a large clinical trial, that is, the Randomized 
Evaluation of Long- Term Anticoagulation Therapy (RE- LY) 
Trial.1,10 An age range of 59–81 years was used to assume 
the varying levels of CrCl and to match with the ages in the 
clinical trial.1 The virtual subjects received multiple doses 
of oral DABE in the presence or absence of the P- gp inhib-
itor verapamil and its metabolite norverapamil. When mul-
tiple doses of oral verapamil (120 mg twice a day (b.i.d.) for 
5 days) were coadministered, the DABE doses were ad-
ministered concurrently with or 2 hours before verapamil. 
The used dosing regimens of DABE and verapamil were 
same as the previous report, which was a DDI study in 
healthy volunteers.6
Pharmacokinetic profiles of DAB were characterized by 
trough concentrations (Ctrough) immediately before the ad-
ministration of the last dose (the day 5 morning dose). The 
Ctrough values are presented as the median and/or 10th/90th 
percentiles of all 20 trials. The simulated Ctrough values were 
compared with the observed data calculated using the dose- 
normalized DAB concentration obtained from the clinical 
trial.10 The DABE dosing regimens were considered appropri-
ate when the predicted 10th/90th percentiles of Ctrough were 
within the reported therapeutic range (28−210 ng/mL).10
RESULTS
Simulation of concentration–time profiles after the 
administration of DABE alone in healthy volunteers
The DABE/DAB PBPK model reproduced observed plasma 
concentration–time profiles of DABE and DAB after a single 
150-mg dose of DABE in healthy volunteers (Figure 1a). 
The geometric mean values of the predicted area under 
the plasma concentration–time curve from time zero to in-
finity (AUC0-∞) and maximum plasma concentration (Cmax) 
were within twofold of the observed values (AUC0-∞, 837 
vs. 899 ng·hour/mL; Cmax, 79 vs. 110 ng/mL).
17 The model 
was also verified by other clinical pharmacokinetic data 
after a single DABE dose (AUC0-∞, 893 vs. 854 ng·hour/mL; 
Cmax, 76 vs. 99 ng/mL).
6 The model recovered observed 
plasma concentration–time profiles of DAB after a multiple 
DABE dose (150 mg b.i.d.): the arithmetic mean values of 
the predicted AUC over the dosing time (AUCτ), peak con-
centration (Cpeak), and Ctrough were within twofold of the 
observed values (AUCτ, 990 vs. 1,120 ng·hour/mL; Cpeak, 
119 vs. 167 ng/mL; Ctrough, 45 vs. 59 ng/mL; Figure 1b).
18
Prediction of P- gp–mediated DDIs in healthy 
volunteers
The PBPK models for the P- gp inhibitors verapamil (and 
norverapamil) and quinidine were verified using the digoxin 
PBPK model (Table 3). The predicted DDI effects (DDI/con-
trol) between digoxin and the P- gp inhibitors were consis-
tent with observed effects.28,29
The DABE/DAB PBPK model reproduced observed 
plasma concentration–time profiles of DAB following a sin-
gle 150-mg dose of DABE 1 hour after verapamil (120 mg 
b.i.d.) in healthy volunteers (Figure 1c).6 The predicted DDI 
effects between DABE and verapamil were consistent with 
the observed effects (AUC ratio, 1.54 vs. 1.54; Cmax ratio, 
1.57 vs. 1.63; Table 3).6 The predicted DDI effects between 
DABE and quinidine were also consistent with the observed 
effects (AUC ratio, 1.48 vs. 1.53; Cmax ratio, 1.48 vs. 1.56; 
Table 3).8 Moreover, the model recovered the observed 
plasma concentration–time profiles of DAB following a sin-
gle 150-mg dose of DABE 2 hours before verapamil (120 mg 
b.i.d.) in healthy volunteers (Figure 1d).6 The predicted AUC 
ratio when DABE was administered 2 hours before ver-
apamil was within twofold of the observed effects (1.31 vs. 
1.18), although the predicted Cmax ratio was slightly over-
estimated relative to the observed effects (1.28 vs. 1.12).6
Simulation of concentration–time profiles after the 
administration of DABE alone in renal impairment 
populations
The DABE/DAB PBPK model recovered the observed 
plasma concentration–time profiles of DAB following a sin-
gle 150-mg dose of DABE in a healthy renal function pop-
ulation and in mild, moderate, and severe renal impairment 
populations (Figure 1e–h).4 The arithmetic mean values of 
the predicted AUC0-∞ and Cmax were within twofold of the 
observed values in the healthy renal function population 
(AUC0-∞, 991 vs. 901 ng·hour/mL; Cmax, 75 vs. 85 ng/mL) and 
in the mild (AUC0-∞, 1,727 vs. 1,580 ng·hour/mL; Cmax, 84 vs. 
109 ng/mL), moderate (AUC0-∞, 2,447 vs. 2,470 ng·hour/mL; 
Cmax, 92 vs. 138 ng/mL), and severe (AUC0-∞, 4,130 vs. 
6,150 ng·hour/mL; Cmax, 108 vs. 205 ng/mL) renal impair-
ment populations.4
Virtual DDI studies between DABE and verapamil in 
renal impairment populations
Virtual DDI studies between DABE and verapamil in renal 
impairment populations were conducted using the DABE/
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Figure 1 Simulated and observed plasma concentration–time profiles of dabigatran etexilate (DABE; red) and dabigatran (DAB; blue) 
after a single oral dose (SD) or multiple doses (MD) of 150 mg DABE. (a) DABE SD alone in healthy volunteer (HV), (b) DABE MD alone 
in HV, (c) DABE SD 1 hour after verapamil (MD) in HV, (d) DABE SD 2 hours before verapamil (MD) in HV, and (e) DABE SD alone in the 
population with healthy renal function (creatinine clearance (CrCl) >80 mL/min) and in the populations with (f) mild (CrCl 50–80 mL/
min), (g) moderate (CrCl 30–50 mL/min), and (h) severe (CrCl 15–30 mL/min) renal impairment. Simulation results are presented as the 
means of all 10 trials (heavy lines), 10 individual trials (thin lines), and 5th and 95th percentiles (dashed lines). Observed data extracted 
from the literature4,6,17,18 are presented as the means (open circles).
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DAB PBPK model (Figure 2). The standard (150 mg b.i.d.) 
and reduced (75 or 110 mg b.i.d.) doses of DABE were 
used in simulations to investigate an appropriate dosing 
regimen for achieving the 10th/90th percentiles of Ctrough 
within the therapeutic range.10 The predicted Ctrough values 
were close to the observed data obtained from the RE- LY 
Trial, which included patients with the coadministration 
of P- gp inhibitors.10 Predicted 10th/90th percentiles of 
Ctrough values in the absence of verapamil were within the 
therapeutic range when 150 mg b.i.d. DABE was adminis-
tered to the mild renal impairment population (37–177 ng/
mL) and 110 mg b.i.d. to the moderate renal impairment 
population (51–203 ng/mL), but these were slightly below 
the lower limit of the therapeutic range when 150 mg b.i.d. 
DABE was administered to the healthy renal function pop-
ulation (23–100 ng/mL). For the severe renal impairment 
population, the predicted values of Ctrough exceeded the 
upper limit of the therapeutic range even when a reduced 
Table 3 Observed and simulated exposure ratio of digoxin and dabigatran etexilate in drug–drug interactions with P-glycoprotein inhibitors 
Inhibitor
Digoxin–inhibitor interactions Dabigatran etexilate–inhibitor interactions
Digoxin 
dosing 
schemes
Inhibitor 
dosing 
schemes
Observed Simulated
Dabigatran 
etexilate dosing 
schemes
Inhibitor 
dosing 
schemes
Observed Simulated
AUC 
ratio
Cmax 
ratio
AUC 
ratio
Cmax 
ratio
AUC 
ratio
Cmax 
ratio
AUC 
ratio
Cmax 
ratio
Training set
Verapamil 0.25 mg, 
b.i.d.
80 mg, 
t.i.d.
1.50 1.44 1.53 1.44 150 mg, single dose 
1 hour after 
verapamil dose
120 mg, 
b.i.d.
1.54 1.63 1.54 1.57
Verification set
Quinidine 0.25 mg, 
q.d.
200 mg, 
q.d.
1.77 1.75 1.64 1.71 150 mg, single dose 200 mg, 
every 
2 hours
1.53 1.56 1.48 1.48
Verapamil — — — — — — 150 mg, single dose 
2 hours before 
verapamil dose
120 mg, 
b.i.d.
1.18 1.12 1.31 1.28
Data are presented as the geometric mean. AUC, area under the plasma concentration–time curve; Cmax, maximum plasma concentration; q.d., once a day; 
b.i.d., twice a day; t.i.d, three times a day.
Figure 2 Simulated and observed trough dabigatran concentrations after multiple dose (75, 110, or 150 mg b.i.d.) of dabigatran etexilate 
(DABE) without, concurrently with, or 2 hours before verapamil in the population with healthy renal function (creatinine clearance 
(CrCl) >80 mL/min) and the populations with mild (CrCl 50–80 mL/min), moderate (CrCl 30–50 mL/min), and severe (CrCl 15–30 
mL/min) renal impairment. Virtual studies were simulated using 20 trials of 10 virtual individuals. Data are presented as the medians 
and 10th/90th percentiles of all 20 trials. Observed concentrations were calculated using dose- normalized concentrations extracted 
from the literature (Randomized Evaluation of Long-Term Anticoagulation Therapy (RE- LY) Trial).10 Lower and upper dotted lines 
indicate 28 ng/mL with 50% increase in the risk of ischemic stroke or systemic embolism and 210 ng/mL with a doubled risk of major 
bleeding, respectively. b.i.d., twice a day.
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dose of 75 mg b.i.d. DABE was administered in the ab-
sence of verapamil (57–229 ng/mL).
Plasma DAB concentrations were simulated in the presence 
of a multiple dose of verapamil (Figure 2). For the healthy renal 
function population, the predicted 10th/90th percentiles of 
Ctrough were 43 to 149 and 28 to 136 ng/mL after 150 mg b.i.d. 
DABE was administered concurrently with and 2 hours before 
verapamil, respectively, which produced DAB concentrations 
within the therapeutic range. The predicted 10th/90th percen-
tiles of Ctrough in the healthy renal function population were 
below the lower limit of the therapeutic range (21–100 ng/mL) 
when 110 mg b.i.d. DABE was administered 2 hours before 
verapamil and within the therapeutic range (31–109 ng/mL) 
when administered concurrently with verapamil. The predicted 
10th/90th percentiles of Ctrough in the mild renal impairment 
population exceeded the upper limit of the therapeutic range 
when 150 mg b.i.d. DABE was administered concurrently 
with and 2 hours before verapamil (82–282 and 57–260 ng/
mL, respectively) and were within the therapeutic range when 
110 mg b.i.d. DABE was administered concurrently with and 
2 hours before verapamil (60–206 and 42–190 ng/mL, respec-
tively). The predicted 10th/90th percentiles of Ctrough in the 
moderate renal impairment population exceeded the upper 
limit of the therapeutic range when 110 mg b.i.d. DABE was 
administered concurrently with and 2 hours before verapamil 
(121–307 and 83–283 ng/mL, respectively) and were within the 
therapeutic range when 75 mg b.i.d. DABE was administered 
concurrently with and 2 hours before verapamil (82–209 and 
57–193 ng/mL, respectively). The median predicted Ctrough in 
the severe renal impairment population exceeded the upper 
limit of the therapeutic range when 75 mg b.i.d. DABE was 
administered concurrently with verapamil (234 ng/mL).
DISCUSSION
This study provides valuable data that were lacking thus 
far concerning the optimization of DABE dosing regimens 
in renal impairment populations who are not routinely as-
sessed as part of clinical DDI studies. The DABE/DAB 
PBPK model was used to predict the DDI effect between 
DABE and the P- gp inhibitor verapamil in populations with 
renal impairment. Virtual DDI studies using PBPK modeling 
revealed that when coadministered with multiple verapamil 
doses, the optimal DABE dosing varied among populations 
with healthy renal function and mild and moderate renal im-
pairment. Specifically, the moderate renal impairment pop-
ulation required a two- stage reduction (75 mg b.i.d.) of the 
DABE dose when coadministered with multiple verapamil 
doses, suggesting that a one- stage reduction (110 mg 
b.i.d.) of the DABE dose was not enough to decrease the 
risk of major bleeding. The present study demonstrates that 
the population- based PBPK model can provide the most 
appropriate dosing regimen of DABE for likely clinical sce-
narios, including DDIs in this renal impairment population 
based on available knowledge of the systems changes and 
in the absence of actual clinical studies.
The DABE/DAB PBPK model was used to predict 
P- gp–mediated DDIs (Figure 2). The accurate prediction 
of P- gp–mediated DDIs in the intestine can be achieved 
using more appropriate parameters for permeability and 
P- gp–mediated efflux in the intestine. Therefore, the values 
of regional Peff,man and P- gp Jmax in the intestine were 
optimized using observed clinical data of bioavailability 
and exposure ratio with the P- gp inhibitors verapamil and 
its metabolite norverapamil.2,6 The model successfully 
predicted DDIs between DABE and the P- gp inhibitors, such 
as verapamil and norverapamil, and quinidine in healthy 
volunteers (Table 3). The previous PBPK modeling for DABE 
and DAB was performed using a static approach in which 
the effective inhibitor concentration is kept unchanged.30 
The static approach is unlikely to simulate plasma DAB 
concentration profiles when the dosing time of verapamil 
shifts from that of DABE, although DDI between DABE and 
verapamil could be minimized if DABE was administered 
2 hours prior to verapamil.6 Our DABE/DAB PBPK model 
in conjunction with the verapamil/norverapamil PBPK 
model could predict the DDI effect when DABE was 
administered 2 hours before verapamil (Table 3). The P- gp 
inhibitory effect of norverapamil is important for estimating 
the P- gp–mediated DDI effect when the dosing time of 
verapamil shifts from that of DABE. The P- gp Ki value for 
norverapamil used in the verapamil/norverapamil PBPK 
model was 0.3 μM as determined based on the literature,26 
because in the preliminary study, the default value (0.04 μM) 
in the Simcyp compound library overestimated the P- gp–
mediated DDI effect when DABE was administered 2 hours 
before verapamil. Thus, these PBPK models can be used to 
investigate P- gp–mediated DDIs in various scenarios.
The DABE/DAB PBPK model could recover plasma con-
centration–time profiles of DAB in renal impairment pop-
ulations (Figure 1f–h). The renal excretion of DAB in the 
model, which was defined using the typical renal clearance 
for healthy male volunteers, predicted DAB elimination from 
the body in virtual renal impairment populations generated 
assuming varying levels of CrCl. The model fulfilled the two-
fold criterion for the difference between the observed and 
predicted exposure parameters: the predicted values of 
AUC0-∞ were in agreement with the observed values, but 
the Cmax values were underestimated regardless of the CrCl 
values in our populations. This underestimation of Cmax was 
attributed to difference in the volume of distribution between 
the early and terminal phases of DAB distribution based on 
the evidence of a multiexponential decrease in DAB con-
centration after intravenous administration.2 Owing to the 
incorporation of distribution volume in the terminal phase, 
the DABE/DAB PBPK model accurately recovered Ctrough 
values of DAB after the repeated administration of DABE 
because of the accurate prediction in the elimination phase 
(Figure 1b). Moreover, the predicted Ctrough values in each 
renal impairment population were also close to observed 
data obtained from the RE- LY Trial.10 These findings suggest 
that this PBPK model can be used for virtual DDI studies in 
renal impairment populations. The predicted DAB concen-
tration profile in the severe renal impairment population was 
underestimated when compared with the observed profile, 
although the predicted exposure parameters were within 
twofold of the observed values (Figure 1h). The metabolic 
enzyme activity and transporter function are suppressed in 
chronic renal failure most likely because of the accumula-
tion of uremic toxins.31 This underestimation in severe renal 
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impairment population may be attributed to the decrease 
of the intestinal P- gp–mediated efflux in the actual patients 
because intestinal P- gp activity is decreased in rats with 
chronic renal failure.31
Virtual DDI studies between DABE and verapamil through 
PBPK modeling were conducted in virtual renal impairment 
populations, which revealed that when the standard dose 
(150 mg b.i.d.) of DABE was administered, the predicted 
90th percentiles of Ctrough for both mild and moderate renal 
impairment populations in the presence of verapamil ex-
ceeded the upper limit of the therapeutic range regardless 
of the dosing time of verapamil (Figure 2). The predicted 
Ctrough values within the therapeutic range were provided 
when 110 mg b.i.d. and 75 mg b.i.d. were administered 
for mild and moderate renal impairment populations, re-
spectively, in the presence of verapamil (Figure 2). These 
results suggest that, when coadministered with a multiple 
verapamil dose, one- stage (110 mg b.i.d.) and two- stage 
(75 mg b.i.d.) reductions of the DABE dose are required for 
mild and moderate renal impairment populations, respec-
tively, if DABE is administered 2 hours before the verapamil 
dose when possible. The US Food and Drug Administration 
has approved the two- stage reduced dose of 75 mg b.i.d. 
in patients with moderate renal impairment only when co-
administered with the strong P- gp inhibitors dronedarone 
or systemic ketoconazole, which is contraindicated in the 
European Union.7,9 The use of P- gp inhibitors, including ve-
rapamil, amiodarone, quinidine, clarithromycin, and ticagre-
lor, does not require DABE dose adjustment in the United 
States.9 The DABE dose of 110 mg b.i.d. is considered in 
the European Union and Japan when DABE is administered 
to patients with either moderate renal impairment or coad-
ministration of a moderate P- gp inhibitor,7,8 whereas the 
recommended dosing is not provided for patients with both 
of these factors. The difference in dosing recommendations 
among the European Union, Japan, and the United States 
can be attributed to the lack of information regarding the op-
timization of DABE dosing in renal impairment populations, 
which are not routinely assessed as part of clinical DDI stud-
ies. Furthermore, the population with healthy renal function 
may not require the reduced DABE dose when coadminis-
tered with a multiple verapamil dose because the predicted 
Ctrough values were within the therapeutic range (Figure 2). 
The DABE dose should not be administered 2 hours be-
fore the verapamil dose when a one- stage reduced DABE 
dose was administered to the population with healthy renal 
function with the coadministration of verapamil because 
the subtherapeutic DAB concentration might be provided 
in a part of the population. Moreover, the predicted 90th 
percentile of Ctrough in the severe renal impairment popula-
tion exceeded the upper limit of the therapeutic range even 
when the two- stage reduced DABE dose was administered 
in both the presence and absence of verapamil, suggesting 
a twofold risk of major bleeding in some patients.
Our study has several limitations for the model verifica-
tion and applicability of the current study. First, the predic-
tive performance of the DABE PBPK model was not directly 
verified using plasma DABE concentration data for renal 
impairment and P- gp–mediated DDI because the observed 
data were not available. The changes in the bioavailability 
of DABE could be reflected in the plasma DAB concen-
trations, which were used in model verification, because 
most of  absorbed DABE is rapidly converted to DAB prior 
to systemic circulation, and DAB is not a substrate of P- 
gp.2,5 Second, DAB has a more simple elimination primarily 
through renal excretion with no contribution of P- gp–medi-
ated active renal tubular secretion.2,5 In case of drugs with 
more complex elimination  such as both renal and hepatic 
eliminations and both passive glomerular  filtration and ac-
tive renal tubular  secretion. The PBPK modeling and sim-
ulation used for complex DDI scenarios need to be further 
verified because renal failure could also affect hepatic me-
tabolism and transporter function.31
In conclusion, the DABE/DAB PBPK model was used to 
predict the DDI effect between DABE and the P- gp inhibitor 
verapamil in renal impairment populations. Virtual DDI stud-
ies between DABE and the P- gp inhibitor verapamil through 
PBPK modeling provided the most appropriate DABE dos-
ing in renal impairment populations coadministered with ver-
apamil. The population- based PBPK model can help simplify 
the optimization of dosing regimen for likely clinical scenar-
ios that cannot be observed during drug development.
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